AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain Life Science Investing
Adamas Announces USFDA Acceptance of New Drug Application for Levodopa-induced Dyskinesia in Patients with Parkinson's Disease Life Science Investing
Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease Life Science Investing
Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa Pharmaceutical Investing
CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate Pharmaceutical Investing
Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress Life Science Investing
